DexCom, Inc. $DXCM Shares Sold by Ethic Inc.

Ethic Inc. cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 38.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,295 shares of the medical device company’s stock after selling 18,910 shares during the quarter. Ethic Inc.’s holdings in DexCom were worth $2,039,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in shares of DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after acquiring an additional 169 shares in the last quarter. Inspire Investing LLC increased its stake in DexCom by 6.1% during the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after purchasing an additional 180 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its holdings in shares of DexCom by 3.2% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after buying an additional 187 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares during the period. Finally, STF Management LP lifted its stake in shares of DexCom by 5.5% during the second quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock worth $353,000 after buying an additional 211 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, Director Richard Alexander Collins sold 2,906 shares of DexCom stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,866 shares of company stock worth $448,177 in the last ninety days. Company insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Truist Financial reissued a “buy” rating and issued a $82.00 target price (down from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Barclays set a $80.00 price objective on DexCom and gave the company an “equal weight” rating in a report on Monday, November 3rd. Weiss Ratings restated a “sell (d+)” rating on shares of DexCom in a research note on Monday. The Goldman Sachs Group dropped their target price on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.61.

DexCom Trading Down 1.0%

DexCom stock opened at $66.37 on Friday. The firm has a market cap of $25.89 billion, a PE ratio of 36.87, a P/E/G ratio of 1.43 and a beta of 1.48. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The stock’s 50 day simple moving average is $63.81 and its two-hundred day simple moving average is $72.73. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.45 earnings per share. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.